Ultramicronized Palmitoylethanolamide and Luteolin: Drug Candidates in Post-COVID-19 Critical Illness Neuropathy and Positioning-Related Peripheral Nerve Injury of the Upper Extremity
Case seriesHumansWith luteolin
This study tested palmitoylethanolamide together with luteolin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Case series
- Subjects
- One 71-year-old man with post-COVID-19 critical illness neuropathy and positioning-related peripheral nerve injury of the left upper extremity
- Dose used in the study
- Ultramicronised palmitoylethanolamide 400 mg plus ultramicronised luteolin 40 mg (branded Glìalia), two tablets a day 12 hours apart
- Duration
- 6 months
- What was measured
- Clinical recovery from critical illness polyneuropathy and positioning-related peripheral nerve injury after treatment with ultramicronised palmitoylethanolamide and luteolin
What the authors reported
This is presented as the first reported successful treatment of post-COVID-19 critical illness neuropathy with positioning-related nerve injury using ultramicronised palmitoylethanolamide and luteolin, described as a pilot case. The authors call for a larger clinical trial to confirm the finding.
Limits of this study
A single case report with no control group; it cannot show effect beyond this one patient. Funding and conflicts not stated in the abstract.
Source
PubMed 38855524 · doi:10.1055/s-0043-1764161
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.